

Figures from 2018

## Creating economic activity

Significant economic value is generated by Novartis, both directly and through the “ripple” effects it creates, including:

### £1.6 billion GDP contribution

**£592 million**  
tax contribution

**£0.9 billion**  
dividend to UK shareholders



**£863 million**  
spend with over 2,000 suppliers

## Impacting lives

Treatments offered by Novartis have an impact on patients lives, potentially allowing them in turn to be more productive workers and consumers:

using a sample of **51 innovative medicines**

we demonstrate that Novartis has a valuable social impact in the UK: by potentially increasing economic activity through improving the quality of life of the working population

**£567 million**  
created in additional GDP in 2018<sup>3</sup>

medical contributions made in MS, heart failure, ophthalmology and cancer

## Saving money for the NHS

Sandoz is a Novartis division devoted to the production and supply of generic and biosimilar medicines:

### £1.98 billion

Sandoz medicines contribute cost savings to the NHS, which can be spent on new medicines and additional healthcare

**Sandoz is a major supplier in the UK**

approximately **450,000**  
patients a month treated with Sandoz generics

**120 million**  
packs distributed to UK patients across almost 300 medicines

## Investing in the future

Novartis invests in and nurtures innovative start-ups, catalysing developments which boost economic output:

### £26 million

Novartis Venture Fund investment in UK companies in the past 5 years including Artios, Binx Health, Bicycle Therapeutics and Silence Therapeutics



Partners with 2 Health Data Research Hubs and Wayra Health Hub, benefiting life sciences across the UK

## Incubating innovation

Novartis generates innovative value spillovers through its innovation and is the number one industry-sponsor of clinical trials in the UK:

### Number 1 in the UK for clinical trials

Novartis is the leading commercial sponsor of clinical trials and in 2018 sponsored 144 clinical trials with 4,196 patients participating

**> 200 projects**  
in clinical development creating the most competitive innovation pipeline

**> £200 million**  
committed to research and development since 2014

## Creating a collaborative ecosystem

Novartis fosters a dynamic multi-disciplinary knowledge-sharing environment. The UK headquarters moved to the White City life sciences cluster in 2019:

### 288 collaborations

with UK academic institutions producing 869 scientific studies in 17 therapy areas (2014-2019)



**Joint collaborations in big data analytics and AI**

including with Oxford Big Data Institute, Microsoft AI Innovation Lab, Benevolent AI and UK BioBank



**More than 7x industry average**  
in contributions towards NHS Joint Working Partnerships

## Supporting a greener industry

Novartis is committed to decreasing its environmental footprint:

### -£45.7 million

environmental impact with ambitious targets to reduce waste and emissions and use of water and energy

<b>Green House gas emissions*</b>	<b>24% less</b>
<b>Water use*</b>	<b>41% less</b>
<b>Waste*</b>	<b>72% less</b>

\*Since 2010

## Generating a skilled workforce

Novartis makes a significant employment impact and nurtures human capital through its collaborative spirit:

### 17,500

full time equivalent jobs supported in UK



**£10.4m**  
spent with UK universities, creating a GDP impact of £29.7 million in 2018

### Women earned more than men on average in 2018

Nearly half of leadership positions are held by women

Novartis UK average

The Europe Economics report “The Economic, Social and Innovation Value Novartis Brings to the UK” was commissioned from Europe Economics by Novartis UK, demonstrating the economic impacts Novartis has upon the UK. All figures are from 2018. [1] [2] Europe Economics considered the wide range of Novartis activities, and assessed how these add value to the UK and the magnitude of this value using the following approaches:

Identifying forms of value from published literature. Quantifying Novartis value by linking facts and figures with economic theory, including a quantification approach which entailed linking information and statistics about Novartis activities to the economic theory. Europe Economics gathered this information through a series of interviews with Novartis personnel across the various areas of activity, and through reviewing company reports and corporate documents.

Quantifying value by developing models. This approach to quantification entailed developing numerical models to apply estimates of value from the literature to Novartis data.

[1] Europe Economics (2019) “The Economic, Social and Innovation Value Novartis Brings to the UK”  
[2] Novartis UK; <https://www.novartis.co.uk/>  
[3] WFOR <http://www.europe-economics.com>